Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1 6Phase NA 1Phase 3 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia 6Neuroblastoma 4Lymphoma 4Leukemia, Myeloid, Acute 4Melanoma 3Sarcoma 2Rhabdomyosarcoma 2Radiation Injuries 2Malignant mesenchymal tumor 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Head and Neck Neoplasms 2Congenital Abnormalities 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Stomatitis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1

Interventions

Rituximab 66Cyclophosphamide 46Vincristine 40Doxorubicin 40Prednisone 35Etoposide 19Radiotherapy 14Gemcitabine 13Peripheral Blood Stem Cell Transplantation 12Filgrastim 12Cytarabine 12Lenalidomide 11Carmustine 10VAP-cyclo protocol 9Prednisolone 9Oxaliplatin 9Melphalan 9Methotrexate 7Ifosfamide 7Mitoxantrone 6Bleomycin 6polatuzumab vedotin 5R-CHOP protocol 4Methylprednisolone 4Injections 4Granulocyte Colony-Stimulating Factor 4Cyclosporine 4Cisplatin 4Carboplatin 4pegfilgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Large B-Cell, Diffuse × sargramostim × Clear all
NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡